

**INITIAL PROOF-OF-CONCEPT RESULTS SHOW INV043 TO BE  
EFFECTIVE AGAINST MULTIPLE CANCER TYPES**

**MELBOURNE (AUSTRALIA) XX May 2021:** Invion Limited (ASX: IVX) ("Invion" or the "Company") is pleased to attach the following presentation on the initial proof-of-concept testing results on INV043, the latest Active Pharmaceutical Ingredient ("API") using the Photosoft™ technology.

These proof-of-concept tests were undertaken in collaboration with Invion's research partner, the Hudson Institute of Medical Research (Hudson Institute), on a number of cancer types.

The key findings from the studies are summarised below:

- Promising preliminary results that may have application across a range of cancers
- INV043 has ~50 times greater phototoxicity than Invion's previous API (IVX-P03) and ~600 times greater than Talaporfin sodium (widely used photosensitiser)
- Studies showed INV043 is selectively retained in malignant but not healthy tissues. Furthermore, no toxicity issues were identified up to 50x the therapeutic dose
- Significant regression was observed *in vivo* in T-cell lymphoma, triple negative breast and pancreatic cancer models
- INV043 also displayed fluorescence characteristics under blue light, which illuminated tumour growths

"These results provide direct proof-of-principle for the use of INV043 as a cancer therapy" said Dr Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers Research Group at Hudson Institute. "These early indications are promising, and may lead to new treatment options for some of the most difficult to treat cancers."

Invion's Chairman and Chief Executive Officer, Thian Chew commented: "By using our latest API, these initial proof-of-concept results demonstrate the potential of Photosoft™ technology's applications in cancer treatment. Our next steps include performing further proof-of-concept studies looking at INV043's effect on the immune response as well as exploring its potential to work together with other therapies."

Further details on the studies are included in the attached presentation.

This announcement has been approved by the Board of Invion.

---

**Investor and Media enquiries:**

Thian Chew (Chairman & CEO)

T: +61 3 8618 6843

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: [brendon@vantagepointpartners.com.au](mailto:brendon@vantagepointpartners.com.au)

## ASX ANNOUNCEMENT

### **About Invion**

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). This announcement was approved for release by Thian Chew, Chairman of the Board. For further information please contact [investor@inviongroup.com](mailto:investor@inviongroup.com).

### **About Photodynamic Therapy (PDT)**

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.